Michael A. Curran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael A. Curran has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Casey R. Ager
Department of Immunology, Mayo Clinic Arizona, Phoenix, AZ 85054
40 shared publications - John Victor Heymach
The University of Texas MD Anderson Cancer Center 1 Department of Thoracic/Head and Neck Medical Oncology Houston, Texas
30 shared publications - Xiuning Le
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
30 shared publications - Yasir Y. Elamin
Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
30 shared publications - Alissa Poteete
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
29 shared publications - Don L. Gibbons
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
29 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
RhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer
Diffuse gastric cancer (DGC) is an aggressive gastric cancer subtype with a poor prognosis. The RHOA Y42C mutation is recurrent in DGC, but its independent oncogenic role is unclear. Next-Generation Sequencing of 431 DGC cases revealed that most RHOA mutations occurred without CDH1 alterations. Using genetically engineered gastric organoids, we show that RhoaY42C, along with KrasG12D and Trp53 loss (RKP), induces DGC, independently of Cdh1 loss. Single-cell and spatial transcriptomics reveal that RKP tumors exhibit mucinous histopathology and a specific lineage trajectory from Aqp5+ cells to Muc1/Muc4+ cells. RKP tumors create an immunosuppressive tumor microenvironment where AREG, transactivated by RhoA Y42C–YAP1, causes T cell exhaustion via PD-1 upregulation. Unlike E-cadherin loss-associated DGC, RKP tumors are highly susceptible to PD-1 blockade. Additionally, the RHOA Y42C mutation correlates with PD-1 upregulation in human DGC samples. These findings redefine the oncogenic role of RhoA Y42C, confirming its sufficiency for DGC development and suggesting PD-1 inhibition as a viable therapeutic option for DGC patients carrying this mutation.
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer
Diffuse gastric cancer (DGC) is an aggressive gastric cancer subtype with a poor prognosis. The RHOA Y42C mutation is recurrent in DGC, but its independent oncogenic role is unclear. Next-Generation Sequencing of 431 DGC cases revealed that most RHOA mutations occurred without CDH1 alterations. Using genetically engineered gastric organoids, we show that RhoaY42C, along with KrasG12D and Trp53 loss (RKP), induces DGC, independently of Cdh1 loss. Single-cell and spatial transcriptomics reveal that RKP tumors exhibit mucinous histopathology and a specific lineage trajectory from Aqp5+ cells to Muc1/Muc4+ cells. RKP tumors create an immunosuppressive tumor microenvironment where AREG, transactivated by RhoA Y42C–YAP1, causes T cell exhaustion via PD-1 upregulation. Unlike E-cadherin loss-associated DGC, RKP tumors are highly susceptible to PD-1 blockade. Additionally, the RHOA Y42C mutation correlates with PD-1 upregulation in human DGC samples. These findings redefine the oncogenic role of RhoA Y42C, confirming its sufficiency for DGC development and suggesting PD-1 inhibition as a viable therapeutic option for DGC patients carrying this mutation.
- Open Access
- 14 April 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody
Background: Checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer immunotherapy; however, their efficacy remains limited in immune-excluded tumors characterized by scarce T-cell infiltration and a profoundly immunosuppressive tumor microenvironment (TME). Activation of the stimulator of interferon genes (STING) pathway represents a promising strategy to overcome immune exclusion by promoting TME remodeling and immune cell recruitment. This study investigated the therapeutic potential of combining 8803, a potent STING agonist with broad cross-species activity, and 27907, a novel Fc-engineered dual-specific antibody targeting PD-L1 and PD-L2, designed to enhance antibody-dependent cytotoxicity and phagocytosis. Methods: The activity of 8803 was assessed in human and murine STING reporter cell lines and in co-culture systems with tumor, endothelial, and immune cells. The Fc-mediated effector functions of 27907 were characterized through ADCC and ADCP reporter bioassays. Antitumor efficacy was evaluated in B16-PD-L2 melanoma (C57BL/6) and TS/A mammary carcinoma (BALB/c) mouse models treated with intratumoral 8803 and/or systemic 27907. Tumor growth and survival were monitored, and immune and vascular remodeling were analyzed by flow cytometry, immunohistochemistry, and immunofluorescence. Statistical analyses were performed using two-way ANOVA with Bonferroni post-test for tumor growth, Mantel–Cox log-rank test for survival, and unpaired Student’s t-test or one-way ANOVA for in vitro and ex vivo data. Results: The combination of 8803 and 27907 resulted in significant tumor growth inhibition and prolonged survival compared with single-agent treatments. STING activation by 8803 remodeled the TME by reducing intratumoral M2-like macrophages and mature regulatory dendritic cells (mregDCs) while enhancing T-cell and myeloid cell infiltration. It also induced PD-L1 and PD-L2 upregulation on tumor and endothelial cells. The dual-specific antibody 27907 efficiently mediated antibody-dependent cellular cytotoxicity and phagocytosis, leading to selective endothelial cell killing, vascular disruption, extensive necrosis, and enhanced immune infiltration in the combination treatment group. Conclusions: Dual PD-L1/PD-L2 blockade synergizes with STING pathway activation to promote immune and vascular remodeling, resulting in superior antitumor efficacy in preclinical tumor models. These findings provide a strong rationale for the clinical development of combination strategies that integrate STING agonists with cytotoxic checkpoint antibodies to overcome immune exclusion and enhance cancer immunotherapy outcomes.
- 14 April 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessTumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody
Background: Checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer immunotherapy; however, their efficacy remains limited in immune-excluded tumors characterized by scarce T-cell infiltration and a profoundly immunosuppressive tumor microenvironment (TME). Activation of the stimulator of interferon genes (STING) pathway represents a promising strategy to overcome immune exclusion by promoting TME remodeling and immune cell recruitment. This study investigated the therapeutic potential of combining 8803, a potent STING agonist with broad cross-species activity, and 27907, a novel Fc-engineered dual-specific antibody targeting PD-L1 and PD-L2, designed to enhance antibody-dependent cytotoxicity and phagocytosis. Methods: The activity of 8803 was assessed in human and murine STING reporter cell lines and in co-culture systems with tumor, endothelial, and immune cells. The Fc-mediated effector functions of 27907 were characterized through ADCC and ADCP reporter bioassays. Antitumor efficacy was evaluated in B16-PD-L2 melanoma (C57BL/6) and TS/A mammary carcinoma (BALB/c) mouse models treated with intratumoral 8803 and/or systemic 27907. Tumor growth and survival were monitored, and immune and vascular remodeling were analyzed by flow cytometry, immunohistochemistry, and immunofluorescence. Statistical analyses were performed using two-way ANOVA with Bonferroni post-test for tumor growth, Mantel–Cox log-rank test for survival, and unpaired Student’s t-test or one-way ANOVA for in vitro and ex vivo data. Results: The combination of 8803 and 27907 resulted in significant tumor growth inhibition and prolonged survival compared with single-agent treatments. STING activation by 8803 remodeled the TME by reducing intratumoral M2-like macrophages and mature regulatory dendritic cells (mregDCs) while enhancing T-cell and myeloid cell infiltration. It also induced PD-L1 and PD-L2 upregulation on tumor and endothelial cells. The dual-specific antibody 27907 efficiently mediated antibody-dependent cellular cytotoxicity and phagocytosis, leading to selective endothelial cell killing, vascular disruption, extensive necrosis, and enhanced immune infiltration in the combination treatment group. Conclusions: Dual PD-L1/PD-L2 blockade synergizes with STING pathway activation to promote immune and vascular remodeling, resulting in superior antitumor efficacy in preclinical tumor models. These findings provide a strong rationale for the clinical development of combination strategies that integrate STING agonists with cytotoxic checkpoint antibodies to overcome immune exclusion and enhance cancer immunotherapy outcomes.
- Top Cited PapersOpen Access
- 16 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
Radiation therapy (RT) is the standard of care for glioblastoma but is not curative. Triggering the cGAS/stimulator of interferon genes (STING) pathway with potent agonists, such as 8803, exerts activity across high-grade glioma preclinical models. To determine if the combination of 8803 with RT warrants consideration in the up-front treatment setting and to clarify the underlying mechanisms of therapeutic activity, C57BL/6J mice harboring intracerebral CT-2A or QPP8v gliomas were treated with RT, intratumoral 8803, or both. The treatment with the combination resulted in 80% long-term survival in the CT-2A model but not in the radiation-resistant QPP8v model. This therapeutic effect was maintained in Sting –/– CT-2A cells, highlighting the direct role of the immune system in mediating the survival benefit. Single-cell RNA-Seq identified increased nitric oxide synthase 2 ( Nos2 ) in inflammatory tumor-associated macrophages; however, the therapeutic effect was maintained in Nos2 –/– mice. Additionally, 8803 reprogrammed the blood-brain barrier (BBB) by altering the Pecam and Cd147 pathways in endothelial cells; intracranial injection of 8803 induced bihemispheric BBB opening for up to 24 hours. Sting activation was visualized longitudinally using 3’-deoxy-3’-[ 18 F]-fluorothymidine ([ 18 F]-FLT) PET, which peaked 72–96 hours after 8803 administration. In summary, 8803 combined with RT triggers distinctive antiglioma immune reactivity, facilitates BBB opening, and warrants consideration for up-front clinical trials in glioblastoma, where treatment effects can be monitored using [ 18 F]-FLT PET imaging.
- 16 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Top Cited PapersOpen AccessSTING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
Radiation therapy (RT) is the standard of care for glioblastoma but is not curative. Triggering the cGAS/stimulator of interferon genes (STING) pathway with potent agonists, such as 8803, exerts activity across high-grade glioma preclinical models. To determine if the combination of 8803 with RT warrants consideration in the up-front treatment setting and to clarify the underlying mechanisms of therapeutic activity, C57BL/6J mice harboring intracerebral CT-2A or QPP8v gliomas were treated with RT, intratumoral 8803, or both. The treatment with the combination resulted in 80% long-term survival in the CT-2A model but not in the radiation-resistant QPP8v model. This therapeutic effect was maintained in Sting –/– CT-2A cells, highlighting the direct role of the immune system in mediating the survival benefit. Single-cell RNA-Seq identified increased nitric oxide synthase 2 ( Nos2 ) in inflammatory tumor-associated macrophages; however, the therapeutic effect was maintained in Nos2 –/– mice. Additionally, 8803 reprogrammed the blood-brain barrier (BBB) by altering the Pecam and Cd147 pathways in endothelial cells; intracranial injection of 8803 induced bihemispheric BBB opening for up to 24 hours. Sting activation was visualized longitudinally using 3’-deoxy-3’-[ 18 F]-fluorothymidine ([ 18 F]-FLT) PET, which peaked 72–96 hours after 8803 administration. In summary, 8803 combined with RT triggers distinctive antiglioma immune reactivity, facilitates BBB opening, and warrants consideration for up-front clinical trials in glioblastoma, where treatment effects can be monitored using [ 18 F]-FLT PET imaging.
- Open Access
- 12 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways
Meningiomas are common tumors of the central nervous system that are typically treated with surgery or radiation, but lack established systemic therapies. Activation of the stimulator of interferon genes pathway with an agonist such as 8803 can trigger anti-tumor immune responses. Using integrated molecular approaches, here we show that this pathway is targetable in both neoplastic and immune populations within the meningioma microenvironment. Meningioma tumor cells exhibit promoter hypomethylation and increased chromatin accessibility of the STING genomic locus, associated with robust expression of this gene. Treatment of diverse patient meningiomas ex vivo with 8803 induces direct tumor cytotoxicity through inflammatory cell death pathways, including induction of gasdermin D membrane pore formation. Release of necrotic tumor debris triggered by 8803 activates macrophages and upregulates matrix metalloproteinase production, facilitating degradation of extra-cellular collagen. Injection of preclinical meningiomas with 8803 induces survival benefits, including in an immunocompetent orthotopic setting, through remodeling of the tumor microenvironment, immune infiltration, and downregulation of tumor-mediated immune suppression, thereby nominating 8803 for treatment consideration in meningiomas.
- 12 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSTING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways
Meningiomas are common tumors of the central nervous system that are typically treated with surgery or radiation, but lack established systemic therapies. Activation of the stimulator of interferon genes pathway with an agonist such as 8803 can trigger anti-tumor immune responses. Using integrated molecular approaches, here we show that this pathway is targetable in both neoplastic and immune populations within the meningioma microenvironment. Meningioma tumor cells exhibit promoter hypomethylation and increased chromatin accessibility of the STING genomic locus, associated with robust expression of this gene. Treatment of diverse patient meningiomas ex vivo with 8803 induces direct tumor cytotoxicity through inflammatory cell death pathways, including induction of gasdermin D membrane pore formation. Release of necrotic tumor debris triggered by 8803 activates macrophages and upregulates matrix metalloproteinase production, facilitating degradation of extra-cellular collagen. Injection of preclinical meningiomas with 8803 induces survival benefits, including in an immunocompetent orthotopic setting, through remodeling of the tumor microenvironment, immune infiltration, and downregulation of tumor-mediated immune suppression, thereby nominating 8803 for treatment consideration in meningiomas.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Development of IL-6 knockout EGFR-mutant GEMM tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Development of IL-6 knockout EGFR-mutant GEMM tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
IL-6 modulates activation state of infiltrating T cells in EGFR mutant tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
IL-6 modulates activation state of infiltrating T cells in EGFR mutant tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Purpose:Patients with advanced non–small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit. Given that IL6 is associated with worse outcomes in patients with NSCLC, we investigate whether IL6 in part contributes to this immunosuppressed phenotype.Experimental Design:We utilized a syngeneic genetically engineered mouse model (GEMM) of EGFR-mutant NSCLC to investigate the effects of IL6 on the tumor microenvironment and the combined efficacy of IL6 inhibition and anti-PD-1 therapy. Corresponding in vitro studies used EGFR-mutant human cell lines and clinical specimens.Results:We identified that EGFR-mutant tumors which have oncogene-independent acquired resistance to EGFR-TKIs were more mesenchymal and had markedly enhanced IL6 secretion. In EGFR-mutant GEMMs, IL6 depletion enhanced activation of infiltrating natural killer (NK)- and T-cell subpopulations and decreased immunosuppressive regulatory T and Th17 cell populations. Inhibition of IL6 increased NK- and T cell–mediated killing of human osimertinib-resistant EGFR-mutant NSCLC tumor cells in cell culture. IL6 blockade sensitized EGFR-mutant GEMM tumors to PD-1 inhibitors through an increase in tumor-infiltrating IFNγ+ CD8+ T cells.Conclusions:These data indicate that IL6 is upregulated in EGFR-mutant NSCLC tumors with acquired EGFR-TKI resistance and suppressed T- and NK-cell function. IL6 blockade enhanced antitumor immunity and efficacy of anti-PD-1 therapy warranting future clinical combinatorial investigations.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Purpose:Patients with advanced non–small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit. Given that IL6 is associated with worse outcomes in patients with NSCLC, we investigate whether IL6 in part contributes to this immunosuppressed phenotype.Experimental Design:We utilized a syngeneic genetically engineered mouse model (GEMM) of EGFR-mutant NSCLC to investigate the effects of IL6 on the tumor microenvironment and the combined efficacy of IL6 inhibition and anti-PD-1 therapy. Corresponding in vitro studies used EGFR-mutant human cell lines and clinical specimens.Results:We identified that EGFR-mutant tumors which have oncogene-independent acquired resistance to EGFR-TKIs were more mesenchymal and had markedly enhanced IL6 secretion. In EGFR-mutant GEMMs, IL6 depletion enhanced activation of infiltrating natural killer (NK)- and T-cell subpopulations and decreased immunosuppressive regulatory T and Th17 cell populations. Inhibition of IL6 increased NK- and T cell–mediated killing of human osimertinib-resistant EGFR-mutant NSCLC tumor cells in cell culture. IL6 blockade sensitized EGFR-mutant GEMM tumors to PD-1 inhibitors through an increase in tumor-infiltrating IFNγ+ CD8+ T cells.Conclusions:These data indicate that IL6 is upregulated in EGFR-mutant NSCLC tumors with acquired EGFR-TKI resistance and suppressed T- and NK-cell function. IL6 blockade enhanced antitumor immunity and efficacy of anti-PD-1 therapy warranting future clinical combinatorial investigations.